12 recruiting, 12 unknown, 4 not yet recruiting, 3 completed. 17 Phase 2, 8 Phase 1, 5 Not applicable, 5 Phase 3, 1 Early Phase 1.
Follow Chemotherapy drug: new trials by email Literature Review of Chemotherapy drug trials Research Report on Chemotherapy drug
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer SBRT+LDRT, Toripalimab, Chemotherapy drug - NSCLC | Phase 2 | Recruiting | Shanghai Chest Hospital | 124 | 2025-02-20 | 2026-03-11 |
| Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid Leukemia ATRA+Venetoclax+Azacitidine, Chemotherapy drug - AML, Adult | Not applicable | Not yet recruiting | The First Affiliated Hospital of Soochow University | 158 | 2025-02-15 | 2025-02-24 |
| DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastases Drug-Eluting Embolic Bead, Chemotherapy drug - Liver Neoplasm, Colorectal Cancer Metastatic | Phase 3 | Recruiting | Tehran University of Medical Sciences | 116 | 2025-01-20 | 2025-04-23 |
| Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer Anlotinib hydrochloride capsule + TQB2450 injection, Chemotherapy drug - Endometrial Cancer | Phase 3 | Not yet recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 420 | 2024-07-01 | 2024-06-27 |
| Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors QLS31905, Oxaliplatin, Capecitabine - Advanced Solid Tumor | Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 360 | 2024-06-30 | 2024-06-06 |
| Cryoablation Versus Medical Therapy in Desmoid Tumors Progressing After Watchful Waiting Cryoablation, Chemotherapy drug - Desmoid Tumor | Not applicable | Recruiting | University Hospital, Strasbourg, France | 150 | 2024-03-04 | 2025-11-19 |
| Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers IMC-R117C, Chemotherapy drug, Kinase inhibitor - Cancer, HLA-A*02:01-positive | Phase 1 / Phase 2 | Recruiting | Immunocore Ltd | 600 | 2024-01-10 | 2026-01-28 |
| Clinical Observational Studies:Integrative TCM and Western Medicine for Breast Cancer Chemotherapy drug, Integrative Treatment (Chemotherapy + TCM) - Breast Cancer | Recruiting | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation | 200 | 2024-01-01 | 2025-07-31 | |
| Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not Transplant, Autologous, Chemotherapy drug - Multiple Myeloma, Minimal Residual Disease | Recruiting | First Affiliated Hospital of Zhejiang University | 210 | 2023-12-01 | 2024-06-24 | |
| CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia anti-CD19 CAR T-cells - B-Cell Non Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia | Phase 1 | Completed | Vinmec Research Institute of Stem Cell and Gene Technology | 18 | 2023-08-02 | 2025-08-26 |
| A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients HLX26, Serplulimab, Chemotherapy drug - NSCLC Stage IV | Phase 2 | Active not recruiting | Shanghai Henlius Biotech | 132 | 2023-07-10 | 2025-08-06 |
| CIETAI and Sequential Radiotherapy in Squamous Lung Cancer bronchial artery interventional therapy, Chemotherapy drug, IMRT - Carcinoma, Non-Small-Cell Lung | Phase 2 | Unknown | Dong Wang | 50 | 2023-07-01 | 2023-08-23 |
| Assess the Efficacy of Radiotherapy and Sequential Chemotherapy and AK104 Before TME Surgery for Local CRC（AK104-IIT-13） AK104 injection, TME surgery, Capecitabine - Locally Advanced Rectal Cancer | Phase 2 | Not yet recruiting | JIN JING | 50 | 2023-04-24 | 2023-04-06 |
| Efficacy of Neoadjuvant Endocrine Therapy Compared to Chemotherapy in Breast Cancer Patients Hormonal Antineoplastics, Chemotherapy drug - Female Breast Cancer | Phase 1 | Unknown | Sohag University | 100 | 2023-04-01 | 2023-03-06 |
| Olaparib Maintenance Therapy in Metastatic Breast Cancer Olaparib, Chemotherapy drug - Metastatic Breast Cancer | Phase 2 | Unknown | National Taiwan University Hospital | 300 | 2023-02-07 | 2024-01-17 |
| Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer Parimparib, Chemotherapy drug, Targeted Therapy Agent - Carcinoma, Non-Small-Cell Lung, EGF-R Positive Non-Small Cell Lung Cancer | Phase 1 | Unknown | Affiliated Hospital of Jiangnan University | 40 | 2022-12-20 | 2024-01-31 |
| Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma Tirelizumab, Nab paclitaxel, Carboplatin - Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Ruijin Hospital | 48 | 2022-11-01 | 2023-11-08 |
| Differences in Rate of Decline in CT-defined Skeletal Muscle Mass and Physical Performance in Patients With Advanced Non-small Cell Lung Cancer Receiving Chemotherapy and Targeted Therapy/Immunotherapy, Before and After Treatment. Chemotherapy drug, Targeted Agent, Immunotherapy - Advanced Lung Cancer, Sarcopenia | Unknown | Prince of Songkla University | 240 | 2022-08-01 | 2024-03-22 | |
| Evaluation of Tumour Growth and Oncological Treatment in Patients With CRLM Using Zebra Fish Embryo Model Chemotherapy drug - Colorectal Cancer Metastatic, Tumour Metastasis | Phase 1 / Phase 2 | Unknown | University Hospital, Linkoeping | 40 | 2022-05-17 | 2023-12-01 |
| Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration ORIC-114, Chemotherapy drug - Solid Tumors | Phase 1 / Phase 2 | Recruiting | ORIC Pharmaceuticals | 350 | 2022-03-10 | 2026-11-05 |
Showing 20 of 34. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (4) · Breast Neoplasms (3) · Burkitt Lymphoma (2) · Neoplasm Metastasis (2) · Adenocarcinoma of Lung (1) · Biliary Tract Neoplasms (1) · Carcinoma, Hepatocellular (1) · Cholangiocarcinoma (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Desmoid Tumors (1) · Endometrial Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Hypopharyngeal Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1)
Eye & ENT Hospital of Fudan University (2) · The First Affiliated Hospital of Soochow University (2) · University Hospital, Linkoeping (2) · Affiliated Hospital of Jiangnan University (1) · Albert Einstein College of Medicine (1) · Ascendis Pharma Oncology Division A/S (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Chinese PLA General Hospital (1) · Dong Wang (1) · First Affiliated Hospital of Zhejiang University (1) · First People's Hospital of Hangzhou (1) · Hebei Medical University Fourth Hospital (1) · Hunan Cancer Hospital (1) · Immunocore Ltd (1) · JIN JING (1)
China (17) · Taiwan (4) · United States (4) · Australia (3) · Italy (3) · Spain (3) · Belgium (2) · Canada (2) · Poland (2) · South Korea (2) · Sweden (2) · Egypt (1) · France (1) · Germany (1) · Hong Kong (1)
Ali Jafarian, MD (1) · Amal Ali, MD (1) · Davis Torrejon-Castro (1) · Haitao Meng (1) · Hongmeng Yu, MD,PhD (1) · Hsien-Chang Wu (1) · Jinhua Huang, Ph.D (1) · Jonathan D Schoenfeld, MD, MPH (1) · Julie M Vose, MD (1) · Liang Zhou, PhD. (1) · Nitin Ohri, MD (1) · Pratik S. Multani, MD, MS (1) · Thanh Liem Nguyen, PhD (1)
PMID 35318277, PMID 35817480, PMID 38261958, PMID 38641773, PMID 40791599, PMID 42098120
2023 (1), P30CA036727 (1)